Anixa Biosciences Inc — Director's Dealing 2021

Jun 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Anixa Biosciences Inc (ANIX)
CIK: 0000715446
Period of Report: 2021-05-31

Reporting Person: KUMAR AMIT (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-01	Employee Stock Option (Right to Buy)	$4.02	A	2000000	Acquired	2031-06-01	Common Stock (2000000)	Direct
2021-06-01	Employee Stock Option (Right to Buy)	$4.02	A	500000	Acquired	2031-06-01	Common Stock (500000)	Direct
2021-05-31	Restricted Stock Award	$0	D	1500000	Disposed	2021-05-31	Common Stock (1500000)	Direct

Footnotes

F1: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2: The options vest and become exercisable as follows: (i) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $5.00, (ii) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $6.00, (iii) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $7.00, and (iv) 500,000 shares vest if during any 5 trading day period, the average closing price of the issuer's common stock is at least $8.00.

F3: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning June 30, 2021.

F4: The vesting requirements were not met and the restricted stock award expired on May 31, 2021.